Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma

Clinical Cancer Research

Volumn 12, Issue 1, 2006, Pages 242-249

  DiJoseph, John F ^a   Dougher, Maureen M ^a   Kalyandrug, Lyka B ^a   Armellino, Douglas C ^a   Boghaert, Erwin R ^a   Hamann, Philip R ^a   Moran, Justin K ^a   Damle, Nitin K ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALICHEAMICIN DERIVATIVE; CD20 ANTIBODY; CD20 ANTIGEN; CD22 ANTIGEN; CMC 544; CYTOTOXIC AGENT; INOTUZUMAB OZOGAMICIN; RITUXIMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

AMINOGLYCOSIDES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD22; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOCONJUGATES; IMMUNOLOGIC FACTORS; LYMPHOMA, B-CELL; MALE; MICE; MICE, NUDE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 31544455876     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1905     Document Type: Article

References (41)

1. DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B lymphoid malignancies. Blood 2004;103:1807-14.
2. Hamann P, Hinman L, Beyer C, et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem 2002;3:40-6.
3. Damle NK. Tumor-targeted chemotherapy using immunoconjugates of calicheamicin. Expert Opin Biol Ther 2004;4:1445-52.
4. Lee M, Dunne T, Chang C, et al. Calicheamicins, a novel family of antibiotics. 4. Structural elucidations of calicheamicins. J Am Chem Soc 1992;114:985-7.
5. I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988;240:1198-201.
6. Thorson J, Sievers E, Ahlert J, et al. Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. Curr Pharm Des 2000;6:1841-79.
7. DiJoseph JF, Goad ME, Dougher MM, et al Potent and specific anti-tumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res 2004;10:8620-9.
8. Grillo-Lopez A. Rituximab (Rituxan/MabThera): the first decade (1993-2003). Expert Rev Anticancer Ther 2003;3:767-79.
9. Coiffier B. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma. Semin Oncol 2004;31:7-11.
10. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005;24:2121-43.
11. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003;14:520-35.
12. Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004;199:1659-69.
13. Gaetano ND, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171:1581-7.
14. Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003;101:949-54.
15. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-76.
16. Non-Hodgkin's lymphoma. Natl Compr Cancer Netw Clin Pract Guidel Oncol 2005;1:1-62.
17. Coiffier B, Herbrecht R, Tilly H, et al. GELA study comparing CHOP and R-CHOP in elderly patients with DLCL: 3-year median follow-up with an analysis according to co-morbidity factors [abstract 2395]. Proc Am Soc Clin Oncol 2003;22:596.
18. Pfreundschuh MG, Trumper L, Ma D, et al. Randomized intergroup trial of first-line treatment for patients ≤60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab-early stopping after the first interim analysis [abstract 6500]. Proc Am Soc Clin Oncol 2004;23:556.
19. DiJoseph JF, Popplewell AG, Tickle S, et al. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol Immunother 2005;54:11-24.
20. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995;47:331-85.
21. Conover WJ, Iman RL. Rank transformation as a bridge between parametric and nonparametric statistics. Am Stat 1981;35:124-9.
22. Stein R, Qu Z, Chen S, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004;10:2868-78.
23. Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, et al. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 2003;9:5866-73.
24. Clynes RA, Towers TL, Tresta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6:443-6.
25. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998;91:1644-52.
26. Rose AL, Smith BE, Maloney DG. Glucocorticoids and rituximab in vitro: synergistic direct anti-proliferative and apoptotic effects. Blood 2002;100:1765-73.
27. Dorshkind K, Pollack SB, Bosma MJ, Phillips RA. Natural killer cells are present in mice with severe combined immunodeficiency (scid). J Immunol 1985;134:3798-801.
28. Greiner DL, Hesselton RA, Schultz LD. SCID mouse models of human stem cell engraftment. Stem Cells 1998;16:166-77.
29. Bertolini F, Fusetti L, Manciso P, et al. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood 2000;96:282-7.
30. Semac I, Palomba C, Kulangara K, et al. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res 2003;63:534-40.
31. Jazirehi AR, Gan X-H, De Vos S, et al. Rituximab (anti-CD20) selectively modifies Bcl-XL and apoptosis protease activating factor-1 (APAF-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2003;2:1183-93.
32. Alas S, Bonavida B, Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Anticancer Res 2000;20:2961-6.
33. Alas S, Ng CP, Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clin Cancer Res 2002;8:836-45.
34. Gaetano ND, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001;114:800-11.
35. Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002;87:33-43.
36. Emmanouilides C, Jazirehi AR, Bonavida B. Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother Radiopharm 2002;17:621-30.
37. Gopal AK, Pagel JM, Hedin N, Press OW. Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. Blood 2004;103:3516-20.
38. Ghetie M, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001;97:1392-8.
39. White CA. Rituxan immunotherapy and zevalin radioimmunotherapy in the treatment of non-Hodgkin's lymphoma. Curr Pharm Biotechnol 2003;4:221-38.
40. Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 2005;23:5044-51.
41. Coleman M, Goldenberg DM, Siegel AB, et al. Epratuzumab: targeting B malignancies through CD22. Blood 2003;9:3991-4s.